October 09, 2020
2 min watch
Save
VIDEO: Ocular Therapeutix sees increased enthusiasm for Dextenza
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this Healio Video Perspective, Antony Mattessich, president and CEO of Ocular Therapeutix, discusses the continuing development of Dextenza (dexamethasone ophthalmic insert 0.4 mg).